Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2014
- Source ID
- 10.1016/j.bbmt.2014.05.020
Entities
People
- Baldeep Wirk
- Edwin P. Alyea
- Gregory A. Hale
- Ian D. Lewis
- Jack W. Hsu
- Jennifer R. Brown
- Jorge Cortés
- Jose F. Leis
- Kwang Woo Ahn
- Mahmoud Aljurf
- Marcos de Lima
- Matt E. Kalaycio
- Matthew D. Seftel
- Mitchell Sabloff
- Rammurti T. Kamble
- Richard T. Maziarz
- Robert Peter Gale
- Ronald M. Sobecks
- Steven Z. Pavletic
- Wael Saber
- Xiaochun Zhu
- Yoshihiro Inamoto
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Incyte
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- United States Public Health Service
- University of Minnesota
- University of Utah